百奥泰收到Hikma支付的1000万美元里程碑付款

Core Viewpoint - Baiotai has entered into a licensing and commercialization agreement with Hikma Pharmaceuticals USA Inc. for the exclusive commercialization rights of BAT2206 (Ustekinumab) injection in the U.S. market, receiving a milestone payment of $10 million from Hikma [1] Group 1 - Baiotai signed the agreement with Hikma on August 27, 2021, granting Hikma the rights to commercialize BAT2206 in the U.S. [1] - The milestone payment of $10 million has been received by Baiotai from Hikma [1] - BAT2206 has been approved for marketing by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with the U.S. brand name being STARJEMZA® and the European brand name Usymro® [1] Group 2 - Baiotai has submitted a marketing application to the National Medical Products Administration (NMPA) in China, which is currently under review [1]